Analysis the cost of chronic obstructive pulmonary disease in Russian Federation

Objective: to evaluate the economic burden of chronic obstructive pulmonary disease (COPD) in Russian Federation. Methods: This paper analyzes the existing evidence base for assessing the value of COPD. The estimation of the economic burden of COPD in Russia using clinical-economic analysis — the «cost of illness» (COI). The study took into account only the direct costs of the state, there were two variants of calculations using statistics in 2007 (according to some indicators more recent data are not available) and extrapolated data based on the incidence in 2012. Results: The economic burden of COPD in Russian Federation (direct costs excluding the costs of drug therapy) for the first version (2007 statistics) calculations was 54.6 billion rubles for the second option (statistics extrapolated to 2012) calculations — 61.6 billion rubles. Structure of direct expenses of the state for the treatment of COPD in Russia was as follows — 77% of hospitalization costs, 21% — the costs of outpatient care, 2% of the cost — emergency medical care. The largest share of costs associated with COPD exacerbation. Conclusion: At the present stage of COPD is an important cause of morbidity and mortality worldwide, resulting in significant economic and social damage, the level of which increases. Prevalence, morbidity and mortality due to this disease varies greatly in different countries and subpopulations within a country and usually depend on the prevalence of smoking. Correct interpretation of the concept of COPD, use of common diagnostic criteria, standardization conducted epidemiological and economic studies are essential estimate of the true damage this disease.

1. Lopez C. J., Murray A. D. et al. Alternative projections of mortality and disability by course 1990—2020: Global Burden of Disease Study. // Lancet. 1997. Vol. 349. P. 1498—1504.

2. Fukuchi Y., Nishimura M., Ichinose M. et al. COPD in Japan: the Nippon COPD epidemiology study. // Respirology. 2004. Vol. 9. P. 458—465.

3. Halbert RJ., Natoli JL., Gano A. et al. Global burden of COPD: systematic review and meta-analysis. // Eur Respir J 2006.

4. Halbert RJ., Isonaka S., George D. et al. Interpreting COPD prevalence estimates: what is the true burden of disease? // Chest 2003;123(5):1684_92.

5. Pellegrino R., Viegi G., Brusasco V. et al. Interpretative strategies for lung function tests. // Eur Respir J 2005;26(5):948-68.

6. Hankinson JL., Odencrantz JR., Fedan KB. Spirometric reference values from a sample of the general US population. // Am J Respir Crit Care Med 1999;159:179-87.

7. Chapman K., Mannino D., Soriano J. et al. Epidemiology and costs of chronic obstructive pulmonary disease. // Eur. Respir. J. 2006. Vol. 27. P. 188—207.

8. Российское респираторное общество. Официальный сайт. http://www.pulmonology.ru/

9. Mannino DM., Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. // Lancet. 2007 Sep 1; 370(9589):765-73.

10. Воробьёв П.А., Авксентьева М.В., Борисенко О.В. и др. Клинико-экономический анализ. Издание 3-е, дополненное, с приложениями. М.: НЬЮДИА-МЕД; 2008

11. Авксентьева М.В., Ильина Н.И. и др. Социально-экономическое бремя бронхиальной астмы и хронической обструктивной болезни лёгких в Российской Федерации. Отчёт по исследованию за 2008-2009 годы. М.: 4ТЕ АРТ, 2010.

12. Статистические материалы Министерства здравоохранения РФ, «Общая заболеваемость взрослого населения РФ за 2012 год», часть IV.

13. Программа государственных гарантий бесплатного оказания гражданам медицинской помощи на 2014 год и на плановый период 2015 и 2016 годов. Постановление правительства Российской Федерации.

14. Рекомендации по способам оплаты специализированной медицинской помощи в стационарных условиях и в дневных стационарах на основе групп заболеваний, в том числе клинико-статистических групп (КСГ) и клинико-профильных групп (КПГ) за счёт средств системы обязательного медицинского страхования. Федеральный фонд обязательного медицинского страхования

15. Masa J.F., Sobradillo V., Villasante C. et al. Costs of chronic obstructive pulmonary disease in Spain: estimation from a population-based study. // Arch. Bronconeumol. 2004. Vol. 40. P. 72—79.

16. Chapman KR., Mannino DM., Soriano JB. et al. Epidemiology and costs of chronic obstructive pulmonary disease. // Eur Respir J 2006; 27(1):188-207.

17. Jansson SA., Andersson F., Borg S. et al. Costs of COPD in Sweden according to disease severity. // Chest 2002;122(6):1994-2002.

18. European Respiratory Society. European Lung White Book: Huddersfi eld, European Respiratory Society Journals, Ltd; 2003.

19. Figueras M., Brosa M., Gisbert R. Th e cost of chronic bronchitis in Spain: Incidence approach. // Revista Espanola de Farmacoeconomia. 1999. №2. P. 33—34.

20. Jansson S., Andersson F., Borg S. et al. Costs of COPD in Sweden according to disease severity. // Chest. 2002. Vol. 122. P. 1994—2002.

21. Miravitlles M., Murio C., Guerrero T. et al. Costs of chronic bronchitis and COPD: A one year follow-up study. // Ibid. 2003. Vol. 123. P. 784—791.

22. National Heart, Lung, and Blood Institute. Morbidity and mortality chartbook on cardiovascular, lung and blood diseases. Bethesda, Maryland: US Department of Health and Human Services, Public Health Service, National Institutes of Health. Accessed at: http://www.nhlbi.nih.gov/resources/docs/cht_book.htm; 2004.

23. U.S. Department of Health and Human Services. National Institutes of Health. National Heart Lung and Blood Institute. Morbidity and Mortality: 2007 Chartbook on Cardiovascular, Lung and Blood Diseases.

24. Hilleman D., Dewan N., Malesker M. et al. Pharmacoeconomic evaluation of COPD. // Ibid. 2000. Vol. 118. P. 1278—1285.